Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell

This study aimed to investigate the combination of inotuzumab ozogamicin (InO; Besponsa) and mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m2  x 4 doses) with or without blinatumomab (Blincyto) in patients with relapsed/refractory (r/r) acute myeloid leukemia (ALL).  

This study concluded that this combination was effective in these patients.  

Some background

Patients with r/r ALL have poorer outcomes. New combinations are needed for these patients. InO and blinatumomab are immunotherapies that have shown good responses in patients with r/r ALL. Low-intensity mini-hyper-CVD involves reduced doses of chemotherapy. The combination of InO and low-intensity mini-hyper-CVD has previously shown good responses in the short term.

However, it was unknown if adding blinatumomab to InO and mini-hyper-CVD would improve outcomes over longer term for patients with r/r ALL. 

Methods & findings

This study involved 96 patients with R/R ALL. Patients were treated with InO and low-intensity mini-hyper-CVD. Some patients received blinatumomab in addition. The average follow-up period was 36 months.

80% of patients had a response to therapy and 57% of these achieved a complete response (CR; no signs of cancer). In patients who responded to treatment, 83% did not have any measurable residual disease (no cancer cells left after treatment).

10% of patients experienced veno-occlusive disease (VOD). VOD is when the blood vessels into and inside the liver become blocked.  

The bottom line

This study concluded that the combination of InO and low-intensity mini-hyper-CVD chemotherapy with or without blinatumomab showed sustained effectiveness in patients with r/r ALL. 

The fine print

Patients were not randomly assigned to blinatumomab. There was no comparison with other regimens. Further studies are needed.

Published By :


Date :

Mar 19, 2021

Original Title :

Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.

click here to get personalized updates